 - Patients must have histologically confirmed rare cancer and must be able to submit specimens; NOTE: Subsequent to sites Institutional Review Board IRB approval of revision 3, patients are NOT required to participate in EAY131 National Cancer Institute NCI-Molecular Analysis for Therapy Choice MATCH to register to this study 